Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
New Supply-Chain Dynamics
Author(s)Jim Miller
As manufacturers move to manufacture to demand rather than to forecast, the traditional wholesaling business model is being transformed.
Advertisement
Articles in this issue
over 22 years ago
Coprocessed Excipients for Solid Dosage Formsover 22 years ago
Manufacturing Execution Systemsover 22 years ago
State-of-the-Art Packaging Machinesover 22 years ago
January 2004over 22 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersover 22 years ago
The Bioterrorism Actover 22 years ago
In the Spotlight--February 2004over 22 years ago
January 2004Advertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
5